{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=9",
    "query": {
      "intervention": "Placebo Administration first",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 1736,
    "total_pages": 174,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T11:30:22.492Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01151423",
      "title": "Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Thrombotic Thrombocytopenic Purpura"
      ],
      "interventions": [
        {
          "name": "Caplacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ablynx, a Sanofi company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2011-01",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2023-04-04",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151423"
    },
    {
      "nct_id": "NCT04899908",
      "title": "Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain Cancer",
        "Brain Metastases",
        "Melanoma",
        "Lung Cancer",
        "Breast Cancer",
        "HER2-positive Breast Cancer",
        "Colorectal Cancer",
        "Gastrointestinal Cancer",
        "SRS",
        "SRT",
        "Whole Brain Radiation",
        "Stereotactic Radiation",
        "AGuIX",
        "Nanoparticle",
        "Cystic",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Stereotactic Radiation",
          "type": "RADIATION"
        },
        {
          "name": "AGuIX gadolinium-based nanoparticles",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2021-09-15",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04899908"
    },
    {
      "nct_id": "NCT00920218",
      "title": "Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "Herpes Zoster Vaccine 1437173A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo vaccine (saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2009-07-14",
      "completion_date": "2012-03-21",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneota",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920218"
    },
    {
      "nct_id": "NCT00871949",
      "title": "Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "PNU-100480",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sequella, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 19,
      "start_date": "2009-04",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2013-08-27",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00871949"
    },
    {
      "nct_id": "NCT01521143",
      "title": "Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epithelial Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Cvac",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Prima BioMed Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 91,
      "start_date": "2012-01",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-12-14",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01521143"
    },
    {
      "nct_id": "NCT00589953",
      "title": "High-Dose Erythropoietin in Extremely Premature Infants to Prevent/Attenuate Brain Injury: A Phase II Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Infant, Premature",
        "Erythropoietin",
        "Brain Injury",
        "Intraventricular Hemorrhage",
        "Periventricular Leukomalacia",
        "Neurodevelopmental Outcomes",
        "Randomized Clinical Trial"
      ],
      "interventions": [
        {
          "name": "Erythropoietin",
          "type": "DRUG"
        },
        {
          "name": "Saline placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atlantic Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Hours",
        "sex": "ALL",
        "summary": "Up to 24 Hours"
      },
      "enrollment_count": 22,
      "start_date": "2007-07",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2013-07-30",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 1,
      "location_summary": "Morristown, New Jersey",
      "locations": [
        {
          "city": "Morristown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589953"
    },
    {
      "nct_id": "NCT04949100",
      "title": "Microcurrent for Fibromyalgia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fibromyalgia"
      ],
      "interventions": [
        {
          "name": "Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief",
          "type": "DEVICE"
        },
        {
          "name": "PLACEBO Microcurrent Transcutaneous Electrical Nerve Stimulator (TENS) for pain relief",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Paul Crawford",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 50,
      "start_date": "2021-10-25",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 1,
      "location_summary": "Nellis Air Force Base, Nevada",
      "locations": [
        {
          "city": "Nellis Air Force Base",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04949100"
    },
    {
      "nct_id": "NCT05891236",
      "title": "Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria"
      ],
      "interventions": [
        {
          "name": "MAM01 1.5 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MAM01 5 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MAM01 10 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MAM01 40 mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MAM01 450 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control",
          "type": "OTHER"
        },
        {
          "name": "MAM01 600 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MAM01 900 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Gates Medical Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 63,
      "start_date": "2023-08-14",
      "completion_date": "2024-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05891236"
    },
    {
      "nct_id": "NCT06668571",
      "title": "Intravenous Ketamine for Treatment-Resistant Depression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Treatment-Resistant",
        "Treatment Resistant Depression (TRD)"
      ],
      "interventions": [
        {
          "name": "Ketamine",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-02-10",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06668571"
    },
    {
      "nct_id": "NCT07892664",
      "title": "Reducing Arterial Inflammation Using Eplerenone and Statins in HIV",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV (Human Immunodeficiency Virus)",
        "Cardiovascular Diseases (CVD)",
        "Arterial Inflammation",
        "Heart Disease"
      ],
      "interventions": [
        {
          "name": "Eplerenone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 124,
      "start_date": "2027-03-01",
      "completion_date": "2031-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-15T11:30:22.492Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07892664"
    }
  ]
}